Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 19, 2020 08:00 ET | Source: Aprea Therapeutics

Aprea Therapeutics to Participate in the 32nd Annual Piper Sandler Healthcare Conference

BOSTON, Nov. 19, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the...
November 05, 2020 16:15 ET | Source: Aprea Therapeutics

Aprea Therapeutics Reports Third Quarter 2020 Financial Results and Provides Update on Business Operations

BOSTON, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the...
October 30, 2020 04:00 ET | Source: Aprea Therapeutics

Aprea Therapeutics to Highlight Changing Treatment Paradigm in MDS as well as Development Pipeline Progress at Virtual R&D Day Today

BOSTON, Oct. 30, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics to reactivate...
October 14, 2020 08:00 ET | Source: Aprea Therapeutics

Aprea Therapeutics Launches Disease Awareness Website for Healthcare Professionals, p53reactivation.com

BOSTON, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics to reactivate...
October 07, 2020 08:00 ET | Source: Aprea Therapeutics

Aprea Therapeutics Receives OK from FDA to Initiate Phase 1 Clinical Studies for Next-Generation Mutant p53 Reactivator, APR-548

BOSTON, Oct. 07, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics Inc., (NASDAQ: APRE), a clinical-stage biotechnology company focused on developing and commercializing novel cancer therapeutics that...
September 29, 2020 08:00 ET | Source: Aprea Therapeutics

Aprea Therapeutics Appoints Michael A. Kelly to Board of Directors

BOSTON, Sept. 29, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics Inc., (NASDAQ: APRE), a clinical-stage biotechnology company focused on developing and commercializing novel cancer therapeutics that...
September 18, 2020 08:00 ET | Source: Aprea Therapeutics

Aprea Therapeutics Promotes Gregory S. Wessels to Chief Commercial Officer and Announces Governance Changes

BOSTON, Sept. 18, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics Inc., (NASDAQ: APRE), a clinical-stage biotechnology company focused on developing and commercializing novel cancer therapeutics that...
September 03, 2020 08:00 ET | Source: Aprea Therapeutics

Aprea Therapeutics to Present at Upcoming Investor Conferences

BOSTON, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate...
August 11, 2020 16:15 ET | Source: Aprea Therapeutics

Aprea Therapeutics Reports Second Quarter 2020 Financial Results and Provides Update on Business Operations

BOSTON, Aug. 11, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate...
July 16, 2020 07:00 ET | Source: Aprea Therapeutics

Aprea Therapeutics Announces Expansion of Clinical Trial Evaluating Eprenetapopt for the Front-Line Treatment of TP53 Mutant Acute Myeloid Leukemia (AML)

Commenced expansion cohort in combination with venetoclax and azacitidineAdded cohort to be activated in combination with azacitidine BOSTON, July 16, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics,...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right